Generating AI analysis...
Revenue
$48.3B
++7.32% YoY
EPS (Basic)
$-4.41
-213.66% YoY
Evidence Layer
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $48.3B | $45.01B | +7.32% |
Cost of Revenue | $13.97B | $10.69B | +30.63% |
Net Income | $-8.95B | $8.03B | -211.50% |
EPS (Basic) | $-4.41 | $3.88 | -213.66% |
EPS (Diluted) | $-4.41 | $3.86 | -214.25% |
R&D Expense | $11.16B | $9.3B | +20.00% |
SG&A Expense | $8.41B | $7.77B | +8.26% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $92.6B | $95.16B | -2.69% |
Current Assets | $29.78B | $31.77B | -6.26% |
Total Liabilities | $76.22B | $65.67B | +16.05% |
Current Liabilities | $23.77B | $22.26B | +6.79% |
Stockholders' Equity | $16.34B | $29.43B | -44.50% |
Cash & Equivalents | $10.35B | $11.46B | -9.75% |
Long-Term Debt | $49.43B | $39.53B | +25.06% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $15.19B | $13.86B | +9.60% |
Investing Cash Flow | $-21.35B | $-2.29B | -830.37% |
Financing Cash Flow | $5.13B | $-9.42B | +154.45% |
Dividends Paid | $4.86B | $4.74B | +2.51% |
Share Buybacks | $0 | $5.16B | -100.00% |
D&A | $9.6B | $9.76B | -1.64% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Net Margin | -18.5% | — | — |
ROE | -54.8% | — | — |
ROA | -9.7% | — | — |
Current Ratio | $1.253 | — | — |
Debt to Equity | $4.666 | — | — |
Other companies in Pharmaceuticals